FDA's meeting page groups the discussed bulk drug substances under BPC-157, emideltide, epitalon, KPV, MOTS-c, Semax, and TB-500 and lists free-base and acetate forms for each of those seven peptide-related groups. 1
FDA's briefing documents say advisory-committee recommendations are nonbinding and that FDA will make final determinations only after completing the committee process and relevant reviews. This update reports the meeting, not a final FDA decision on any substance. 2345678
What this source can tell us. PeptideScanner is reporting the cited regulator or label record. The summary does not extend that record into broader safety, effectiveness, or approval claims.